

## DAFTAR PUSTAKA

- Abbas, A. K., Lichtman, A. H. and Pillai, S. (eds) (2018a) 'Differentiation and Functions of CD8+ Effector T Cells', in *Cellular and Molecular Immunology*. 9th edn. Philadelphia: Elsevier, pp. 243–250.
- Abbas, A. K., Lichtman, A. H. and Pillai, S. (eds) (2018b) 'Immunity to Tumors', in *Cellular and Molecular Immunology*. 9th edn. Philadelphia: Elsevier, pp. 397–416.
- Abbas, A. K., Lichtman, A. H. and Pillai, S. (eds) (2018c) 'Immunologic Tolerance and Autoimmunity', in *Cellular and Molecular Immunology*. 9th edn. Philadelphia: Elsevier, pp. 325–350.
- Al-Saleh, K. *et al.* (2017) 'Predictive and Prognostic Significance of CD8 + Tumor - infiltrating lymphocytes in Patients with Luminal B/HER 2 Negative Breast Cancer Treated with Neoadjuvant Chemotherapy', *Oncology*, 14, pp. 337–344. doi: 10.3892/ol.2017.6144.
- Barriga, V. *et al.* (2019) 'The Complex Interaction between the Tumor Micro-Environment and Immune Checkpoints in Breast Cancer', *Cancers*, 11(8), pp. 1–21. doi: 10.3390/cancers11081205.
- Bray, F. *et al.* (2018) 'Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries', *CA: A Cancer Journal for Clinicians*, 68, pp. 394–424. doi: 10.3322/caac.21492.
- Collins, L. C. (2018) 'Breast', in Goldblum, J. R. *et al.* (eds) *Rosai and*

*Ackerman's Surgical Pathology*. 11th edn. Philadelphia: Elsevier, pp. 1434–1529.

Dunn, G. P. *et al.* (2002) 'Cancer Immunoediting: from Immunosurveillance to Tumor Escape', *Nature Publishing Group*, 3(11), pp. 991–998. Available at: [www.nature.com/natureimmunology](http://www.nature.com/natureimmunology).

Dunn, G. P., Old, L. J. and Schreiber, R. D. (2004) 'The Immunobiology of Cancer Immunosurveillance and Immunoediting', *Immunity*, 21, pp. 137–148.

Ellenson, L. H. and Lester, S. C. (2018) 'Female Genital System and Breast', in Kumar, V., Abbas, A. K., and Aster, J. C. (eds) *Robbins Basic Pathology*. 10th edn. Philadelphia: Elsevier, pp. 736–747.

Evangelou, Z. *et al.* (2020) 'PD-L1 Expression and Tumor-Infiltrating Lymphocytes in Breast Cancer: Clinicopathological Analysis in Women Younger than 40 Years Old', *In Vivo*, 34(2), pp. 639–647. doi: 10.21873/invivo.11818.

Guan, J. *et al.* (2017) 'Programmed Death Ligand-1 (PD-L1) Expression in the Programmed Death Receptor-1 (PD-1)/PD-L1 Blockade', *Archives of Pathology & Laboratory Medicine*, 141(6), pp. 851–861. doi: 10.5858/arpa.2016-0361-RA.

Guo, L., Lin, Y. and Kwok, H. F. (2017) 'The Function and Regulation of PD-L1 in Immunotherapy', *ADMET & DMPK*, 5(3), pp. 159–172. doi: 10.5599/admet.5.3.442.

- Hanahan, D. and Weinberg, R. A. (2017) 'Biological Hallmarks of Cancer', *Holland-Frei Cancer Medicine*, pp. 1–10. doi: 10.1002/9781119000822.hfcm002.
- He, J. *et al.* (2018) 'Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications', *American Journal of Clinical Pathology*, 149(3), pp. 253–261. doi: 10.1093/ajcp/aqx162.
- Ju, X. *et al.* (2020) 'Regulation of PD-L1 Expression in Cancer and Clinical Implications in Immunotherapy', *American Journal of Cancer Research*, 10(1), pp. 1–11.
- 'Kanker Payudara' (2016) *InfoDATIN*. Jakarta: Pusat Data dan Informasi Kementrian Kesehatan RI, pp. 1–9.
- Karnik, T. *et al.* (2018) 'PD-L1 in Breast Cancer : Comparative Analysis of 3 Different Antibodies', *Human Pathology*, 72, pp. 28–34. doi: 10.1016/j.humpath.2017.08.010.
- Kumar, Vinay; Abbas, A. A. J. (ed.) (2015) *Robbins & Cotran Pathologic Basis of Disease*. 9th edn. Philadelphia: Elsevier Saunders.
- Kurozumi, S. *et al.* (2019) 'Clinicopathological Values of PD-L1 Expression in HER2-positive Breast Cancer', *Scientific Reports*. Springer US, 9(16662), pp. 1–8. doi: 10.1038/s41598-019-52944-6.
- Lakhani, S. (2012) *WHO Classification of Tumours of The Breast*. 4th edn. Edited by M. Lakhani, Sunil; Ellis, Ian; Schnitt, Stuart; Tan, Puay; van de Vijver. Lyon, France: International Agency for Research on

Cancer. doi: 10.1017/CBO9781107415324.004.

Mahmoud, S. M. A. *et al.* (2011) 'Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer', *Journal of Clinical Oncology*, 29(15), pp. 1949–1955. doi: 10.1200/JCO.2010.30.5037.

Ni, J. and Ni, A. (2018) 'Landscape of PD-1/PD-L1 Regulation and Targeted Immunotherapy', *Chinese Medical Sciences Journal*, 33(3), pp. 174–182. doi: 10.24920/21804.

Peng, G. *et al.* (2019) 'CD8+ cytotoxic and FoxP3+ regulatory T lymphocytes serve as prognostic factors in breast cancer', *American Journal of Translational Research*, 11(8), pp. 5039–5053.

Available at:  
<http://www.ajtr.org/files/ajtr0098553.pdf>  
<http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emexb&NEWS=N&AN=2003907947>.

Rakha, E., Allison, K., Ellis, I., *et al.* (2019) 'Invasive Breast Carcinoma: General Overview', in Lokuhetty, D. *et al.* (eds) *WHO Classification of Tumours Breast Tumours*. 5th edn. France: International Agency for Research on Cancer (IARC), pp. 82–101.

Rakha, E., Allison, K., Bu, H., *et al.* (2019) 'Invasive Breast Carcinoma of No Special Type', in Lokuhetty, D. *et al.* (eds) *WHO Classification of Tumours Breast Tumours*. 5th edn. France: International Agency for Research on Cancer (IARC), pp. 102–109.

Rathore, A. S. *et al.* (2014) 'are predictors of favourable survival outcome

in infiltrating ductal carcinoma of breast', *Indian Journal of Medical Research*, 26, pp. 361–369.

Salgado, R. *et al.* (2017) 'The Evaluation of Tumor-infiltrating lymphocytes (TILs) in breast cancer : Recommendations by an International TILs Working Group 2014', *Annals of Oncology*, 26, pp. 259–271. doi: 10.1093/annonc/mdu450.

Toss, A. *et al.* (2017) 'Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?', *International Journal of Molecular Sciences*, 18(85), pp. 1–24. doi: 10.3390/ijms18010085.

Wang, Z. Q. *et al.* (2017) 'PD-L1 and Intratumoral Immune Response in Breast Cancer', *Oncotarget*, 8(31), pp. 51641–51651. doi: 10.18632/oncotarget.18305.

Zhou, T. *et al.* (2018) 'Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis', *Anti-Cancer Drugs*, 29(9), pp. 904–910. doi: 10.1097/CAD.0000000000000683.



KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN  
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN  
KOMITE ETIK PENELITIAN KESEHATAN  
RSPTN UNIVERSITAS HASANUDDIN  
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR  
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu  
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.





Contact Person: dr. Agussalim Bukhari, M.Med, PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

**REKOMENDASI PERSETUJUAN ETIK**

Nomor : 130/UN4.6.4.5.31/ PP36/ 2021

Tanggal: 26 Februari 2021

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

|  |  |   |                           |
|--|--|---|---------------------------|
| No Protokol                                      | UH21020107   | No Sponsor Protokol   |                           |
| Peneliti Utama                                   | <b>dr. Astuti</b>  | Sponsor   |                           |
| Judul Peneliti                                   | EKSPRESI PROGRAMMED DEATH-LIGAND 1(PD-L1)DAN CD8+ PADA PENDERITA KARSINOMA PAYUDARA INVASIF (INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE) |   |                           |
| No Versi Protokol                                | 1  | Tanggal Versi   | 22 Februari 2021          |
| No Versi PSP                                     |  | Tanggal Versi   |                           |
| Tempat Penelitian                                | <b>Laboratorium Patologi Anatomi Fakultas Kedokteran Universitas Hasanuddin Makassar</b>   |   |                           |
| Jenis Review                                     | <input checked="" type="checkbox"/> Exempted<br><input type="checkbox"/> Expedited<br><input type="checkbox"/> Fullboard Tanggal           | Masa Berlaku<br>26 Februari 2021<br>sampai<br>26 Februari 2022  | Frekuensi review lanjutan |
| Ketua Komisi Etik Penelitian Kesehatan FKUH      | Nama<br><b>Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)</b>  | Tanda tangan<br> |                           |
| Sekretaris Komisi Etik Penelitian Kesehatan FKUH | Nama<br><b>dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)</b>   | Tanda tangan<br> |                           |

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

| NO | NO SLIDE | UMUR (TAHUN) | GRADE | EKSPRESI PD-L1 | EKSPRESI CD8+ |
|----|----------|--------------|-------|----------------|---------------|
| 1  | 1706     | 67           | 1     | 1              | 1             |
| 2  | 1334     | 45           | 1     | 2              | 2             |
| 3  | 1441     | 45           | 1     | 1              | 2             |
| 4  | 2569     | 57           | 1     | 1              | 2             |
| 5  | 0280     | 45           | 1     | 1              | 1             |
| 6  | 0366     | 43           | 1     | 2              | 2             |
| 7  | 1261     | 47           | 1     | 1              | 2             |
| 8  | 2262     | 51           | 1     | 2              | 1             |
| 9  | 3336     | 50           | 1     | 2              | 2             |
| 10 | 4597     | 43           | 1     | 1              | 2             |
| 11 | 0704     | 41           | 1     | 1              | 2             |
| 12 | 0035     | 58           | 1     | 1              | 2             |
| 13 | 0181     | 52           | 1     | 1              | 1             |
| 14 | 034      | 45           | 1     | 1              | 2             |
| 15 | 879      | 42           | 1     | 1              | 1             |
| 16 | 1132     | 28           | 1     | 1              | 1             |
| 17 | 552      | 31           | 1     | 1              | 1             |
| 18 | 017      | 56           | 2     | 1              | 2             |
| 19 | 0121     | 51           | 2     | 1              | 1             |
| 20 | 0242     | 58           | 2     | 1              | 1             |
| 21 | 0305     | 40           | 2     | 1              | 1             |
| 22 | 0403     | 42           | 2     | 1              | 2             |
| 23 | 0527     | 49           | 2     | 2              | 1             |
| 24 | 0610     | 40           | 2     | 1              | 1             |
| 25 | 0647     | 39           | 2     | 2              | 1             |
| 26 | 0894     | 50           | 2     | 1              | 2             |
| 27 | 1497     | 59           | 2     | 1              | 1             |
| 28 | 1733     | 43           | 2     | 2              | 1             |
| 29 | 1798     | 46           | 2     | 2              | 1             |
| 30 | 1987     | 66           | 2     | 1              | 1             |
| 31 | 2481     | 38           | 2     | 1              | 1             |
| 32 | 2531     | 37           | 2     | 1              | 1             |
| 33 | 2670     | 49           | 2     | 2              | 1             |
| 34 | 2833     | 46           | 2     | 1              | 1             |
| 35 | 2899     | 48           | 2     | 2              | 1             |
| 36 | 2925     | 42           | 2     | 1              | 1             |
| 37 | 2985     | 41           | 2     | 2              | 1             |

|    |      |    |   |   |   |
|----|------|----|---|---|---|
| 38 | 3258 | 58 | 2 | 1 | 1 |
| 39 | 3545 | 67 | 2 | 1 | 1 |
| 40 | 3578 | 46 | 2 | 2 | 1 |
| 41 | 3641 | 45 | 2 | 2 | 1 |
| 42 | 3754 | 39 | 2 | 1 | 2 |
| 43 | 3897 | 51 | 2 | 2 | 1 |
| 44 | 4002 | 53 | 2 | 1 | 2 |
| 45 | 4447 | 48 | 2 | 1 | 1 |
| 46 | 4648 | 49 | 2 | 1 | 1 |
| 47 | 4679 | 54 | 2 | 1 | 1 |
| 48 | 4807 | 45 | 2 | 1 | 1 |
| 49 | 4827 | 50 | 2 | 1 | 2 |
| 50 | 3343 | 39 | 3 | 1 | 2 |
| 51 | 4574 | 63 | 3 | 1 | 1 |
| 52 | 1490 | 35 | 3 | 1 | 2 |
| 53 | 1993 | 50 | 3 | 1 | 2 |
| 54 | 2590 | 49 | 3 | 1 | 2 |
| 55 | 2598 | 65 | 3 | 1 | 1 |
| 56 | 4678 | 44 | 3 | 1 | 1 |
| 57 | 0294 | 63 | 3 | 1 | 2 |
| 58 | 2167 | 51 | 3 | 1 | 1 |
| 59 | 1394 | 45 | 3 | 1 | 1 |
| 60 | 1810 | 66 | 3 | 1 | 1 |
| 61 | 2016 | 40 | 3 | 1 | 1 |
| 62 | 2104 | 54 | 3 | 1 | 2 |
| 63 | 2142 | 53 | 3 | 1 | 2 |
| 64 | 2166 | 57 | 3 | 1 | 2 |
| 65 | 2230 | 44 | 3 | 1 | 2 |
| 66 | 2344 | 56 | 3 | 1 | 1 |
| 67 | 2551 | 44 | 3 | 1 | 1 |
| 68 | 2707 | 53 | 3 | 1 | 1 |
| 69 | 2816 | 36 | 3 | 1 | 1 |
| 70 | 3130 | 45 | 3 | 1 | 1 |
| 71 | 3157 | 46 | 3 | 1 | 1 |
| 72 | 3196 | 59 | 3 | 1 | 1 |
| 73 | 3233 | 35 | 3 | 1 | 2 |
| 74 | 3495 | 44 | 3 | 1 | 1 |
| 75 | 3629 | 48 | 3 | 2 | 1 |
| 76 | 3771 | 70 | 3 | 2 | 1 |



|    |      |    |   |   |   |
|----|------|----|---|---|---|
| 77 | 3988 | 38 | 3 | 1 | 1 |
| 78 | 4334 | 54 | 3 | 2 | 1 |
| 79 | 4685 | 67 | 3 | 1 | 1 |
| 80 | 4718 | 43 | 3 | 1 | 2 |

KETERANGAN

|                |             |
|----------------|-------------|
| GRADE          | 1 = GRADE 1 |
|                | 2 = GRADE 2 |
|                | 3 = GRADE 3 |
| EKSPRESI PD-L1 | 1 = POSITIF |
|                | 2 = NEGATIF |
| EKSPRESI CD8+  | 1 = LOW     |
|                | 2 = HIGH    |

## Frequencies

### Notes

|                        |                                |  |
|------------------------|--------------------------------|--|
| Output Created         |                                | 27-JUL-2021 09:07:14   |
| Comments               |                                |  |
| Input                  | Active Dataset                 | DataSet2   |
|                        | Filter                         | <none>   |
|                        | Weight                         | <none>   |
|                        | Split File                     | <none>   |
|                        | N of Rows in Working Data File | 80   |
| Missing Value Handling | Definition of Missing          | User-defined missing values are treated as missing.  |
|                        | Cases Used                     | Statistics are based on all cases with valid data.   |
| Syntax                 |                                | FREQUENCIES VARIABLES=PDL1<br>CD8 GRADE UMUR<br><br>/BARChart FREQ<br><br>/ORDER=ANALYSIS. |
| Resources              | Processor Time                 | 00:00:03,72  |
|                        | Elapsed Time                   | 00:00:02,38  |

[DataSet2]

### Statistics

|   |         | PDL1 | CD8 | GRADE | UMUR |
|---|---------|------|-----|-------|------|
| N | Valid   | 80   | 80  | 80    | 80   |
|   | Missing | 0    | 0   | 0     | 0    |

### Frequency Table

NEW FILE.

DATASET NAME DataSet1 WINDOW=FRONT.

NEW FILE.

DATASET NAME DataSet2 WINDOW=FRONT.

FREQUENCIES VARIABLES=PDL1 CD8 GRADE UMUR

/BARCHART FREQ

/ORDER=ANALYSIS.

**PDL1**

|       |         | Frequency | Percent | Valid Percent | Cumulative Percent |
|-------|---------|-----------|---------|---------------|--------------------|
| Valid | POSITIF | 63        | 78.8    | 78.8          | 78.8               |
|       | NEGATIF | 17        | 21.3    | 21.3          | 100.0              |
|       | Total   | 80        | 100.0   | 100.0         |                    |

**CD8**

|       |       | Frequency | Percent | Valid Percent | Cumulative Percent |
|-------|-------|-----------|---------|---------------|--------------------|
| Valid | HIGH  | 27        | 33.8    | 33.8          | 33.8               |
|       | LOW   | 53        | 66.3    | 66.3          | 100.0              |
|       | Total | 80        | 100.0   | 100.0         |                    |

**GRADE**

|       |         | Frequency | Percent | Valid Percent | Cumulative Percent |
|-------|---------|-----------|---------|---------------|--------------------|
| Valid | GRADE 1 | 17        | 21.3    | 21.3          | 21.3               |
|       | GRADE 2 | 32        | 40.0    | 40.0          | 61.3               |

|         |    |       |       |       |
|---------|----|-------|-------|-------|
| GRADE 3 | 31 | 38.8  | 38.8  | 100.0 |
| Total   | 80 | 100.0 | 100.0 |       |

### UMUR

|                 | Frequency | Percent | Valid Percent | Cumulative Percent |
|-----------------|-----------|---------|---------------|--------------------|
| Valid <40 TAHUN | 11        | 13.8    | 13.8          | 13.8               |
| >=40 TAHUN      | 69        | 86.3    | 86.3          | 100.0              |
| Total           | 80        | 100.0   | 100.0         |                    |

### CROSSTABS

/TABLES=PDL1 CD8 BY GRADE

/FORMAT=AVALUE TABLES

/STATISTICS=CHISQ

/CELLS=COUNT COLUMN

/COUNT ROUND CELL

/BARCHART

/METHOD=EXACT TIMER(5).

### Crosstabs

**Notes**

|                        |  |   |
|------------------------|--|---|
| Output Created         | 27-JUL-2021 09:10:11   |   |
| Comments               |  |   |
| Input                  | Active Dataset   | DataSet2  |
|                        | Filter   | <none>  |
|                        | Weight   | <none>  |
|                        | Split File   | <none>  |
|                        | N of Rows in Working Data File   | 80  |
| Missing Value Handling | Definition of Missing  | User-defined missing values are treated as missing.   |
|                        | Cases Used   | Statistics for each table are based on all the cases with valid data in the specified range(s) for all variables in each table. |
| Syntax                 | <pre> CROSSTABS   /TABLES=PDL1 CD8 BY GRADE   /FORMAT=AVALUE TABLES   /STATISTICS=CHISQ   /CELLS=COUNT COLUMN   /COUNT ROUND CELL   /BARCHART   /METHOD=EXACT TIMER(5).           </pre> |   |

|           |                           |             |
|-----------|---------------------------|-------------|
| Resources | Processor Time            | 00:00:02,55 |
|           | Elapsed Time              | 00:00:01,32 |
|           | Dimensions Requested      | 2           |
|           | Cells Available           | 349496      |
|           | Time for Exact Statistics | 0:00:00,13  |

**Case Processing Summary**

|              | Cases |         |         |         |       |         |
|--------------|-------|---------|---------|---------|-------|---------|
|              | Valid |         | Missing |         | Total |         |
|              | N     | Percent | N       | Percent | N     | Percent |
| PDL1 * GRADE | 80    | 100.0%  | 0       | 0.0%    | 80    | 100.0%  |
| CD8 * GRADE  | 80    | 100.0%  | 0       | 0.0%    | 80    | 100.0%  |

**PDL1 \* GRADE**

**Crosstab**

|  |       |       |
|--|-------|-------|
|  | GRADE | Total |
|--|-------|-------|

|       |                |                | GRADE 1 | GRADE 2 | GRADE 3 |        |
|-------|----------------|----------------|---------|---------|---------|--------|
| PDL1  | POSITIF        | Count          | 13      | 22      | 28      | 63     |
|       |                | % within GRADE | 76.5%   | 68.8%   | 90.3%   | 78.8%  |
|       | NEGATIF        | Count          | 4       | 10      | 3       | 17     |
|       |                | % within GRADE | 23.5%   | 31.3%   | 9.7%    | 21.3%  |
| Total | Count          |                | 17      | 32      | 31      | 80     |
|       | % within GRADE |                | 100.0%  | 100.0%  | 100.0%  | 100.0% |

#### Chi-Square Tests

|                                 | Value              | df | Asymptotic<br>Significance<br>(2-sided) | Exact Sig. (2-<br>sided) | Exact Sig. (1-<br>sided) |  |
|---------------------------------|--------------------|----|---|--------------------------|--------------------------|--|
| Pearson Chi-Square              | 4.446 <sup>a</sup> | 2  | .108                                    | .115                     |                          |  |
| Likelihood Ratio                | 4.748              | 2  | .093                                    | .117                     |                          |  |
| Fisher's Exact Test             | 4.530              |    |   | .115                     |                          |  |
| Linear-by-Linear<br>Association | 2.047 <sup>b</sup> | 1  | .153                                    | .207                     | .106                     |  |
| N of Valid Cases                | 80                 |    |   |                          |                          |  |

#### Chi-Square Tests

|                    | Point Probability |
|--------------------|-------------------|
| Pearson Chi-Square |                   |
| Likelihood Ratio   |                   |



|                              |      |
|------------------------------|------|
| Fisher's Exact Test          |      |
| Linear-by-Linear Association | .052 |
| N of Valid Cases             |      |

a. 1 cells (16,7%) have expected count less than 5. The minimum expected count is 3,61.

b. The standardized statistic is -1,431.

## CD8 \* GRADE

Crosstab

|       |      |                | GRADE   |         |         | Total  |
|-------|------|----------------|---------|---------|---------|--------|
|       |      |                | GRADE 1 | GRADE 2 | GRADE 3 |        |
| CD8   | HIGH | Count          | 10      | 6       | 11      | 27     |
|       |      | % within GRADE | 58.8%   | 18.8%   | 35.5%   | 33.8%  |
|       | LOW  | Count          | 7       | 26      | 20      | 53     |
|       |      | % within GRADE | 41.2%   | 81.3%   | 64.5%   | 66.3%  |
| Total |      | Count          | 17      | 32      | 31      | 80     |
|       |      | % within GRADE | 100.0%  | 100.0%  | 100.0%  | 100.0% |

**Chi-Square Tests**

|                                 | Value              | df | Asymptotic<br>Significance<br>(2-sided) | Exact Sig. (2-<br>sided) | Exact Sig. (1-<br>sided) |  |
|---------------------------------|--------------------|----|---|--------------------------|--------------------------|--|
| Pearson Chi-Square              | 8.042 <sup>a</sup> | 2  | .018                                    | .017                     | .158                     |  |
| Likelihood Ratio                | 8.054              | 2  | .018                                    | .022                     |                          |  |
| Fisher's Exact Test             | 7.844              |    |   | .021                     |                          |  |
| Linear-by-Linear<br>Association | 1.345 <sup>b</sup> | 1  | .246                                    | .277                     |                          |  |
| N of Valid Cases                | 80                 |    |   |                          |                          |  |

**Chi-Square Tests**

|                              | Point Probability |
|------------------------------|-------------------|
| Pearson Chi-Square           | .063              |
| Likelihood Ratio             |                   |
| Fisher's Exact Test          |                   |
| Linear-by-Linear Association |                   |
| N of Valid Cases             |                   |

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 5,74.

b. The standardized statistic is 1,160.

CROSSTABS

/TABLES=PDL1 BY CD8

```

/FORMAT=AVALUE TABLES

/STATISTICS=CHISQ

/CELLS=COUNT COLUMN

/COUNT ROUND CELL

/BARCHART

/METHOD=EXACT TIMER(5).

```

## Crosstabs

### Notes

|                |                                |          |
|----------------|--------------------------------|----------|
| Output Created | 27-JUL-2021 09:16:13           |          |
| Comments       |                                |          |
| Input          | Active Dataset                 | DataSet2 |
|                | Filter                         | <none>   |
|                | Weight                         | <none>   |
|                | Split File                     | <none>   |
|                | N of Rows in Working Data File | 80       |

|                        |                           |   |
|------------------------|---------------------------|---|
| Missing Value Handling | Definition of Missing     | User-defined missing values are treated as missing.   |
|                        | Cases Used                | Statistics for each table are based on all the cases with valid data in the specified range(s) for all variables in each table.   |
| Syntax                 |                           | <p>CROSSTABS</p> <p>/TABLES=PDL1 BY CD8</p> <p>/FORMAT=AVALUE TABLES</p> <p>/STATISTICS=CHISQ</p> <p>/CELLS=COUNT COLUMN</p> <p>/COUNT ROUND CELL</p> <p>/BARCHART</p> <p>/METHOD=EXACT TIMER(5).</p> |
| Resources              | Processor Time            | 00:00:01,08   |
|                        | Elapsed Time              | 00:00:00,40   |
|                        | Dimensions Requested      | 2   |
|                        | Cells Available           | 349496  |
|                        | Time for Exact Statistics | 0:00:00,02  |

### Case Processing Summary

| Cases |         |         |         |       |         |
|-------|---------|---------|---------|-------|---------|
| Valid |         | Missing |         | Total |         |
| N     | Percent | N       | Percent | N     | Percent |
|       |         |         |         |       |         |

|            |    |        |   |      |    |        |
|------------|----|--------|---|------|----|--------|
| PDL1 * CD8 | 80 | 100.0% | 0 | 0.0% | 80 | 100.0% |
|------------|----|--------|---|------|----|--------|

**PDL1 \* CD8 Crosstabulation**

|       |              |              | CD8    |        | Total |
|-------|--------------|--------------|--------|--------|-------|
|       |              |              | HIGH   | LOW    |       |
| PDL1  | POSITIF      | Count        | 24     | 39     | 63    |
|       |              | % within CD8 | 88.9%  | 73.6%  | 78.8% |
|       | NEGATIF      | Count        | 3      | 14     | 17    |
|       |              | % within CD8 | 11.1%  | 26.4%  | 21.3% |
| Total | Count        | 27           | 53     | 80     |       |
|       | % within CD8 | 100.0%       | 100.0% | 100.0% |       |

**Chi-Square Tests**

|                                    | Value              | df | Asymptotic<br>Significance<br>(2-sided) | Exact Sig. (2-<br>sided) | Exact Sig. (1-<br>sided) |  |
|------------------------------------|--------------------|----|---|--------------------------|--------------------------|--|
| Pearson Chi-Square                 | 2.504 <sup>a</sup> | 1  | .114                                    | .152                     | .095                     |  |
| Continuity Correction <sup>b</sup> | 1.673              | 1  | .196                                    |                          |                          |  |
| Likelihood Ratio                   | 2.724              | 1  | .099                                    | .152                     | .095                     |  |
| Fisher's Exact Test                |                    |    |   | .152                     | .095                     |  |
| Linear-by-Linear<br>Association    | 2.472 <sup>c</sup> | 1  | .116                                    | .152                     | .095                     |  |

|                  |    |  |  |  |  |
|------------------|----|--|--|--|--|
| N of Valid Cases | 80 |  |  |  |  |
|------------------|----|--|--|--|--|

**Chi-Square Tests**

|                                    | Point Probability |
|------------------------------------|-------------------|
| Pearson Chi-Square                 |                   |
| Continuity Correction <sup>b</sup> |                   |
| Likelihood Ratio                   |                   |
| Fisher's Exact Test                |                   |
| Linear-by-Linear Association       | .069              |
| N of Valid Cases                   |                   |

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 5,74.

b. Computed only for a 2x2 table

c. The standardized statistic is 1,572.